Adverse outcomes and an immunosuppressed endotype in septic patients with reduced IFN-γ ELISpotEvan L. Barrios, Charles C. Caldwell, Marvin L. Dirain et al.|JCI Insight|2023Cited by 21
Determining potential immunomodulatory drug efficacy in sepsis using ELISpotAndrew H. Walton, Richard S. Hotchkiss, Monty B. Mazer et al.|Scientific Reports|2025Cited by 7
Adverse Long-Term Outcomes and an Immune Suppressed Endotype in Sepsis Patients with Reduced Interferon-γ ELISpot: A Multicenter, Prospective Observational StudyEvan A. Barrios, Charles C. Caldwell, Monty B. Mazer et al.|medRxiv|2023Cited by 4
Development and optimization of a diluted whole blood ELISpot assay to test immune functionRicardo Ungaro, Thomas S. Griffith, Julie Xu et al.|Journal of Immunological Methods|2024Cited by 4
Development and optimization of a diluted whole blood ELISpot assay to test immune functionRicardo Ungaro, Thomas S. Griffith, Julie Xu et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 1